HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Neutral rating on CytomX Therapeutics (NASDAQ:CTMX).

June 27, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Neutral rating on CytomX Therapeutics. This suggests that the analyst does not foresee significant short-term movement in the stock price.
The reiteration of a Neutral rating by HC Wainwright & Co. indicates that the analyst does not expect significant changes in the stock's performance in the short term. This is a signal to investors that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100